ORIC Pharmaceuticals Inc
The Vice President of Biostatistics provides strategic and operational leadership for all biostatistics activities across the company's clinical development portfolio, focusing on lung and prostate cancer indications. This role involves overseeing statistical strategy, trial design, and data interpretation while supporting global regulatory submissions and approvals. The position requires deep expertise in statistical methodologies and the ability to lead cross-functional teams in a dynamic, fast-paced environment.
Headquarters
South San Francisco, California, United States
Company Size
51-200 employees
Founded
2014
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies that target cancer resistance mechanisms. The company's pipeline includes rinzimetostat and enozertinib, which are being evaluated in clinical trials for cancers such as prostate cancer and non-small cell lung cancer (NSCLC). ORIC's resistance platform addresses innate, acquired, and bypass resistance to improve the efficacy and duration of existing cancer treatments.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ORIC Pharmaceuticals Inc.
52% above the average for this role
Associate Director, Biostatistics
Bristol Myers Squibb
Senior Director, Biostatistics
Rhythm Pharmaceuticals
Associate Director, Biostatistics
PepGen
Vice President, Biostatistics
Crescent Biopharma
Senior Manager, Biostatistics
Bristol Myers Squibb
Senior Manager, Biostatistics
Sun Pharmaceutical Industries Limited